Positive results with lenvatinib for the treatment of advanced medullary thyroid cancer in a phase II trial

2015 ◽  
Vol 11 (11) ◽  
pp. 632-632
Keyword(s):  
Thyroid Cancer ◽  
Phase Ii ◽  
Medullary Thyroid Cancer ◽  
Phase Ii Trial ◽  
Medullary Thyroid ◽  
Positive Results

A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer

2007 ◽  
Vol 26 (2) ◽  
pp. 183-188 ◽  
Author(s):  
Athanassios Argiris ◽  
Sanjiv S. Agarwala ◽  
Michalis V. Karamouzis ◽  
Lynn A. Burmeister ◽  
Sally E. Carty
Keyword(s):  
Thyroid Cancer ◽  
Interferon Alpha ◽  
Phase Ii ◽  
Medullary Thyroid Cancer ◽  
Phase Ii Trial ◽  
Medullary Thyroid ◽  
Interferon Alpha 2B

Phase II trial of sunitinib in medullary thyroid cancer (MTC).

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 5504-5504 ◽  
Author(s):  
J. A. De Souza ◽  
N. Busaidy ◽  
A. Zimrin ◽  
T. Y. Seiwert ◽  
V. M. Villaflor ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Phase Ii ◽  
Medullary Thyroid Cancer ◽  
Phase Ii Trial ◽  
Medullary Thyroid

scholarly journals A Phase II Trial of the Multi-Targeted Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer (MTC)

2012 ◽  
Vol 23 ◽  
pp. xi35-xi36 ◽  
Author(s):  
M. Schlumberger ◽  
B. Jarzab ◽  
M.E. Cabanillas ◽  
B. Robinson ◽  
P. Furio ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Phase Ii ◽  
Medullary Thyroid Cancer ◽  
Kinase Inhibitor ◽  
Phase Ii Trial ◽  
Medullary Thyroid

Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 6018-6018 ◽  
Author(s):  
S. A. Wells ◽  
J. E. Gosnell ◽  
R. F. Gagel ◽  
J. F. Moley ◽  
D. G. Pfister ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Disease Control ◽  
Phase Ii ◽  
Tyrosine Kinases ◽  
Medullary Thyroid Cancer ◽  
Phase Ii Trial ◽  
Locally Advanced ◽  
Disease Control Rate ◽  
Clinical Activity ◽  
Medullary Thyroid

6018 Background: Medullary thyroid cancer (MTC) is the most common cause of death in patients with hereditary syndromes caused by activating mutations in the RET protooncogene. RET activation is the initial oncogenic event, with the activity of other receptor tyrosine kinases, including VEGFR and EGFR, likely to contribute to tumor growth and metastasis. Vandetanib (ZD6474) is a once- daily oral agent that selectively targets RET, VEGFR and EGFR tyrosine kinases. Methods: Eligible patients had unresectable, measurable, locally advanced or metastatic hereditary MTC and a RET germline mutation. Patients received vandetanib 300 mg/day until disease progression or any other withdrawal criteria. The primary objective was to assess the objective tumor response (RECIST every 3 months). Secondary assessments included disease control rate, biochemical response (determined by decrements in plasma levels of calcitonin, a tumor marker for MTC) and safety and tolerability. Results: Thirty patients (21 female; median age 50 years) received initial treatment with vandetanib 300 mg. At data cut-off (20 Nov 2006), the median duration of treatment was 172 days. Based on site investigator assessments, 20% (6/30) of patients experienced a partial response (duration of response 59–260 days) and another 30% (9/30) of patients experienced stable disease =24 weeks, yielding a disease control rate of 50% (15/30). Centralized independent confirmation of response is planned. In 19 patients, plasma calcitonin levels showed a =50% decrease from baseline that was maintained for at least 6 weeks. Adverse events (AEs) occurring in >50% of patients were rash (73%), diarrhea (67%), fatigue (57%) and nausea (53%). Most AEs were grade 1 or 2; grade 3 AEs included asymptomatic QTc prolongation (n=5), rash and diarrhea (both n=3), all of which were manageable. Conclusions: Vandetanib has demonstrated clinical activity in this phase II study in metastatic hereditary MTC, and the safety profile is generally consistent with previous vandetanib monotherapy studies. Accrual is now complete (30 patients), and an updated analysis will be performed in April 2007. An international, randomized, placebo-controlled phase II trial of vandetanib in MTC is now recruiting patients. # No significant financial relationships to disclose.

First Line Sorafenib Treatment for Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis

2018 ◽  
Vol 127 (04) ◽  
pp. 240-246 ◽  
Author(s):  
Judit Kocsis ◽  
Éva Szekanecz ◽  
Ali Bassam ◽  
Andrea Uhlyarik ◽  
Zsuzsanna Pápai ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tyrosine Kinase ◽  
Disease Control ◽  
Tyrosine Kinase Inhibitors ◽  
Phase Ii ◽  
Medullary Thyroid Cancer ◽  
Kinase Inhibitors ◽  
Efficacy And Safety ◽  
First Line ◽  
Medullary Thyroid

Abstract Background Medullary thyroid cancer (MTC) is a rare disease, the prognosis of advanced and metastatic disease is poor and few therapeutic options are available in this setting. Based on the results of phase II and III studies with sorafenib in differentiated thyroid cancer and the lack of availability of registered tyrosine kinase inhibitors, vandetabin and cabozantinib in Hungary, we designed a uncontrolled, prospective efficacy and safety study of patients with metastatic MTC treated with first-line sorafenib in five Hungarian oncology centers. Methods Ten consecutive patients with progressive or symptomatic metastatic MTC were included and started sorafenib 400  mg twice a day between June 2012 and March 2016. The primary end point was median progression-free survival (mPFS). Secondary endpoints included disease control rate, biochemical response, symptomatic response and toxicity. Results Four patients achieved partial remission (40%) according to RECIST 1.1 evaluation. Five patients had stable disease beyond 12 months (50%) and one patient had progressive disease (10%). Median PFS was 19.1 months. The disease control rate was 90%. Association between radiologic response and biochemical or symptomatic response was inconsistent. Most common side effects were Grade 1-2 fatigue (60%), palmar-plantar erythrodysesthesia, rash/dermatitis 50-50%, alopecia 40%. Conclusions In our prospective case series in patients with MTC first-line sorafenib showed at least similar efficacy as in other small phase II trials and case reports. Based on comparable efficacy with registered tyrosine kinase inhibitors and it’s manageable toxicity profile, we believe that sorafenib has role in the sequential treatment of MTC.

Sign in / Sign up

Export Citation Format

Share Document